Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During ...

Eli Lilly and Company saw its stock price ascend on Tuesday, buoyed by promising reports about orforglipron, its ...

Nvov Nordisk stock rose after a study showed Ozempic reduced the risk of heart attack, stroke and death by 23% compared with ...